Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q2 2025 · 10-Q
Revenue$0.00$0.00derivedno prior Q2 2024 on file Net Income$13.29M$13.29M+44.2% vs Q2 2024 EPS Diluted$0.31$0.31+40.9% vs Q2 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Operating Income-$2,489,000N/M Operating Cash Flowderived-$3,535,000N/M Free Cash Flowderived-$3,539,000N/M ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end